Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Evotec 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Evotec 3Q

Revenues decline in the quarter, up 8% YTD

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec

3Q Revenues: €22.2 million (-16%)

3Q Earnings: €5.9 million (-30%)

YTD Revenues: €64.2 million (+8%)

YTD Earnings: €7.5 million (-18%)

Comments: YTD growth was driven by an increase in revenues from the company’s drug discovery alliances, Andromeda/Teva, Boehringer Ingelheim (€2.5 million) and Novartis, and revenues from upfront payments from the CureBeta partnership with Janssen and contributions from acquisitions of Evotec Munich and Evotec San Francisco.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics